171 related articles for article (PubMed ID: 30312217)
1. Diagnostic and prognostic value of 18F-FDG PET/CT imaging in suspected recurrence of male breast cancer.
Vadi SK; Mittal BR; Sood A; Singh G; Bal A; Parihar AS; Bhattacharya A; Basher RK; Kapoor R
Nucl Med Commun; 2019 Jan; 40(1):63-72. PubMed ID: 30312217
[TBL] [Abstract][Full Text] [Related]
2. Do 18F-FDG PET/CT findings have a relationship with histopathological and immunohistochemical factors of breast cancer in men?
Vatankulu B; Işik G; Kocael P; Kuyumcu S; Ilvan Ş; Sağer S; Halaç M; Türkmen C; Sönmezoğlu K
Nucl Med Commun; 2016 Dec; 37(12):1273-1281. PubMed ID: 27472037
[TBL] [Abstract][Full Text] [Related]
3. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic and Prognostic Value of 18F-FDG PET/CT in Male Breast Cancer: Results From a Bicentric Population.
Evangelista L; Bertagna F; Bertoli M; Stela T; Saladini G; Giubbini R
Curr Radiopharm; 2016; 9(2):169-77. PubMed ID: 26018128
[TBL] [Abstract][Full Text] [Related]
5. The role of
Angelini A; Ceci F; Castellucci P; Graziani T; Polverari G; Trovarelli G; Palmerini E; Ferrari S; Fanti S; Ruggieri P
Eur J Nucl Med Mol Imaging; 2017 Sep; 44(10):1712-1720. PubMed ID: 28405727
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET/CT in Diagnostic and Prognostic Evaluation of Patients With Suspected Recurrence of Chondrosarcoma.
Vadi SK; Mittal BR; Gorla AKR; Sood A; Basher RK; Sood A; Kakkar N; Sen RK
Clin Nucl Med; 2018 Feb; 43(2):87-93. PubMed ID: 29261626
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Melsaether AN; Raad RA; Pujara AC; Ponzo FD; Pysarenko KM; Jhaveri K; Babb JS; Sigmund EE; Kim SG; Moy LA
Radiology; 2016 Oct; 281(1):193-202. PubMed ID: 27023002
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic value of 18F-FDG PET/CT in comparison with morphological imaging in primary adrenal gland malignancies - a multicenter experience.
Cistaro A; Niccoli Asabella A; Coppolino P; Quartuccio N; Altini C; Cucinotta M; Alongi P; Balma M; Sanfilippo S; Buschiazzo A; Piccardo A; Fanelli M; Sambuceti G; Bomanji J; Baldari S; Bisi G; Fanti S; Rubini G
Hell J Nucl Med; 2015; 18(2):97-102. PubMed ID: 26187207
[TBL] [Abstract][Full Text] [Related]
9. Clinical utility of 18F-FDG PET/CT in low 18F-FDG-avidity breast cancer subtypes: comparison with breast US and MRI.
Park HL; Yoo IR; O JH; Kim H; Kim SH; Kang BJ
Nucl Med Commun; 2018 Jan; 39(1):35-43. PubMed ID: 28984814
[TBL] [Abstract][Full Text] [Related]
10. Whole-body
Gajjala SR; Hulikal N; Kadiyala S; Kottu R; Kalawat T
Indian J Med Res; 2018 Mar; 147(3):256-262. PubMed ID: 29923514
[TBL] [Abstract][Full Text] [Related]
11. Incremental Value of Cocktail 18F-FDG and 18F-NaF PET/CT Over 18F-FDG PET/CT Alone for Characterization of Skeletal Metastases in Breast Cancer.
Roop MJ; Singh B; Singh H; Watts A; Kohli PS; Mittal BR; Singh G
Clin Nucl Med; 2017 May; 42(5):335-340. PubMed ID: 28263210
[TBL] [Abstract][Full Text] [Related]
12. Detection of distant metastasis and prognostic prediction of recurrent salivary gland carcinomas using
Lee SH; Roh JL; Kim JS; Lee JH; Choi SH; Nam SY; Kim SY
Oral Dis; 2018 Sep; 24(6):940-947. PubMed ID: 29688610
[TBL] [Abstract][Full Text] [Related]
13. Clinical and prognostic value of 18F-FDG-PET/CT in restaging of pancreatic cancer.
Albano D; Familiari D; Gentile R; Scalisi S; Midiri F; Messina M; Spada M; Fornito MC; Galia M; Midiri M; Alongi P
Nucl Med Commun; 2018 Aug; 39(8):741-746. PubMed ID: 29782393
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
Orsaria P; Chiaravalloti A; Caredda E; Marchese PV; Titka B; Anemona L; Portarena I; Schillaci O; Petrella G; Palombi L; Buonomo OC
Anticancer Res; 2018 Dec; 38(12):6639-6652. PubMed ID: 30504372
[TBL] [Abstract][Full Text] [Related]
15.
Ulaner GA; Juarez J; Riedl CC; Goldman DA
J Nucl Med; 2019 Apr; 60(4):472-477. PubMed ID: 30237211
[No Abstract] [Full Text] [Related]
16. 18F-FDG PET/CT for the prediction and detection of local recurrence after radiofrequency ablation of malignant lung lesions.
Singnurkar A; Solomon SB; Gönen M; Larson SM; Schöder H
J Nucl Med; 2010 Dec; 51(12):1833-40. PubMed ID: 21078787
[TBL] [Abstract][Full Text] [Related]
17. Detection of bone metastases in breast cancer patients in the PET/CT era: Do we still need the bone scan?
Caglar M; Kupik O; Karabulut E; Høilund-Carlsen PF
Rev Esp Med Nucl Imagen Mol; 2016; 35(1):3-11. PubMed ID: 26514321
[TBL] [Abstract][Full Text] [Related]
18. ¹⁸F-FDG-PET/CT in staging, restaging, and treatment response assessment of male breast cancer.
Groheux D; Hindié E; Marty M; Espié M; Rubello D; Vercellino L; Bousquet G; Ohnona J; Toubert ME; Merlet P; Misset JL
Eur J Radiol; 2014 Oct; 83(10):1925-33. PubMed ID: 24985086
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
20. Predictive value of (18)F-FDG PET/CT in restaging patients affected by ovarian carcinoma: a multicentre study.
Caobelli F; Alongi P; Evangelista L; Picchio M; Saladini G; Rensi M; Geatti O; Castello A; Laghai I; Popescu CE; Dolci C; Crivellaro C; Seghezzi S; Kirienko M; De Biasi V; Cocciolillo F; Quartuccio N;
Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):404-13. PubMed ID: 26381775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
